Curated News
By: NewsRamp Editorial Staff
January 04, 2025
Investors Alert: Securities Class Action Lawsuit Against Applied Therapeutics, Inc.
Discuss on Reddit
LinkedIn
TelegramTLDR
- Lead plaintiff deadline is February 18, 2025, giving advantage to early participants in the lawsuit against Applied Therapeutics, Inc.
- Defendants allegedly failed to adhere to trial protocol for drug candidate govorestat, risking FDA rejection for New Drug Application.
- Kessler Topaz Meltzer & Check, LLP aims to protect investors from fraud, seeking justice for victims of corporate misconduct.
- Investors can seek lead plaintiff status in the class action lawsuit against Applied Therapeutics, Inc. by February 18, 2025.
Impact - Why it Matters
This news matters as it highlights alleged misconduct by Applied Therapeutics, potentially impacting investors who purchased securities during the specified period. Investors are urged to take action before the lead plaintiff deadline to potentially recover losses and participate in the legal process. The outcome of this lawsuit could have significant implications for the pharmaceutical industry and investor protection.
Summary
A securities class action lawsuit has been filed against Applied Therapeutics, Inc. by the law firm of Kessler Topaz Meltzer & Check, LLP on behalf of investors who purchased securities between January 3, 2024, and December 2, 2024. The complaint alleges that Applied Therapeutics did not adhere to trial protocol and good clinical practices for its drug candidate, govorestat, posing a risk of FDA rejection. Investors have until February 18, 2025, to seek lead plaintiff status through legal counsel.
Source Statement
This curated news summary relied on this press release disributed by NewMediaWire. Read the source press release here, Investors Alert: Securities Class Action Lawsuit Against Applied Therapeutics, Inc.
